Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Irving

Showing results (301-310 of 321) with videos related to

Pageof 33
Sort By:
Hepatology (Baltimore, Md.)|April 11, 2012
Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humansJames Pritchett, Emma Harvey, Varinder Athwal, et al.
Eclinicalmedicine|February 20, 2025
Occult hepatitis B virus infection: risk for a blood supply, but how about individuals' health?Michael X Fu, Ahmed Elsharkawy, Brendan Healy, et al.
Genes and Immunity|April 19, 2013
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infectionV Suppiah, N J Armstrong, K S O'Connor, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
Plos Pathogens|December 21, 2010
HIV capsid is a tractable target for small molecule therapeutic interventionWade S Blair, Chris Pickford, Stephen L Irving, et al.
Journal of Viral Hepatitis|May 18, 2021
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapyDavid A Smith, Daniel Bradshaw, Jean L Mbisa, et al.
EMBO Molecular Medicine|November 8, 2017
SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosisVarinder S Athwal, James Pritchett, Jessica Llewellyn, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Elife|September 4, 2019
Interferon lambda 4 impacts the genetic diversity of hepatitis C virusM Azim Ansari, Elihu Aranday-Cortes, Camilla Lc Ip, et al.
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Pageof 33

Showing results (301-310 of 321) with videos related to

Sort By:
Pageof 33
Hepatology (Baltimore, Md.)|April 11, 2012
Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humansJames Pritchett, Emma Harvey, Varinder Athwal, et al.
Eclinicalmedicine|February 20, 2025
Occult hepatitis B virus infection: risk for a blood supply, but how about individuals' health?Michael X Fu, Ahmed Elsharkawy, Brendan Healy, et al.
Genes and Immunity|April 19, 2013
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infectionV Suppiah, N J Armstrong, K S O'Connor, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
Plos Pathogens|December 21, 2010
HIV capsid is a tractable target for small molecule therapeutic interventionWade S Blair, Chris Pickford, Stephen L Irving, et al.
Journal of Viral Hepatitis|May 18, 2021
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapyDavid A Smith, Daniel Bradshaw, Jean L Mbisa, et al.
EMBO Molecular Medicine|November 8, 2017
SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosisVarinder S Athwal, James Pritchett, Jessica Llewellyn, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Elife|September 4, 2019
Interferon lambda 4 impacts the genetic diversity of hepatitis C virusM Azim Ansari, Elihu Aranday-Cortes, Camilla Lc Ip, et al.
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Pageof 33